Concord Biosciences Overview
- Year Founded
-
1986

- Status
-
Acquired/Merged
- Employees
-
200

- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
2
Concord Biosciences General Information
Description
Provider of contract research and chemical development services. The company's services offers comprehensive capabilities and conducts studies with all species commonly used in nonclinical research providing study information with insightful analysis enabling its clients in the Agricultural Chemicals industry with a comprehensive, integrated suite of services to accelerate drug development through all phases of drug development.
Contact Information
Website
www.concordbio.comCorporate Office
- 10845 Wellness Way
- Concord, OH 44077
- United States
Corporate Office
- 10845 Wellness Way
- Concord, OH 44077
- United States
Concord Biosciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Concord Biosciences Comparisons
Industry
Financing
Details
Concord Biosciences Competitors (20)
One of Concord Biosciences’s 20 competitors is Shin Nippon Biomedical Laboratories, a Corporation company based in Kagoshima, Japan.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Shin Nippon Biomedical Laboratories | Corporation | Kagoshima, Japan | ||||
Aragen Life Sciences | Private Equity-Backed | Hyderabad, India | ||||
TCG Lifesciences | Corporation | Kolkata, India | ||||
Eurofins Advinus | Corporate Backed or Acquired | Bangalore, India | ||||
Syngene International | Formerly PE-Backed | Bangalore, India |
Concord Biosciences Patents
Concord Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9697994-B1 | Use of stable label compounds with accelerator mass spectrometry | Inactive | 09-Apr-2015 | ||
US-20150259278-A1 | Crystalline forms of neurotrophin mimetic compounds and their salts | Inactive | 27-Sep-2012 | ||
US-20170158653-A1 | Crystalline forms of neurotrophin mimetic compounds and their salts | Active | 27-Sep-2012 | ||
US-9884833-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | Active | 27-Sep-2012 | ||
US-20120004310-A1 | Non-peptide bdnf neurotrophin mimetics | Inactive | 28-May-2010 | C07C33/30 |
Concord Biosciences Signals
Concord Biosciences Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Concord Biosciences Investments (2)
Concord Biosciences’s most recent deal was a Early Stage VC with Celerion. The deal was made on 01-Aug-2010.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Celerion | 01-Aug-2010 | Early Stage VC | BPO/Outsource Services | ||
MDS (Discovery & Pre-clinical Operations) | 08-Mar-2010 | Buyout/LBO | Drug Delivery |
Concord Biosciences Exits (1)
Concord Biosciences’s most recent exit was on 01-Aug-2010 from Celerion. The exit was categorized as with 3 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Celerion | 01-Aug-2010 | Completed |
|
Concord Biosciences FAQs
-
When was Concord Biosciences founded?
Concord Biosciences was founded in 1986.
-
Where is Concord Biosciences headquartered?
Concord Biosciences is headquartered in Concord, OH.
-
What is the size of Concord Biosciences?
Concord Biosciences has 200 total employees.
-
What industry is Concord Biosciences in?
Concord Biosciences’s primary industry is Drug Discovery.
-
Is Concord Biosciences a private or public company?
Concord Biosciences is a Private company.
-
What is the current valuation of Concord Biosciences?
The current valuation of Concord Biosciences is
. -
What is Concord Biosciences’s current revenue?
The current revenue for Concord Biosciences is
. -
How much funding has Concord Biosciences raised over time?
Concord Biosciences has raised $5.1M.
-
Who are Concord Biosciences’s investors?
Bain Capital Ventures, Charter Life Sciences, Early Stage Partners, Everett Partners, and Main Market Partners are 5 of 9 investors who have invested in Concord Biosciences.
-
Who are Concord Biosciences’s competitors?
Shin Nippon Biomedical Laboratories, Aragen Life Sciences, TCG Lifesciences, Eurofins Advinus, and Syngene International are some of the 20 competitors of Concord Biosciences.
-
When was Concord Biosciences acquired?
Concord Biosciences was acquired on 01-Apr-2018.
-
Who acquired Concord Biosciences?
Concord Biosciences was acquired by Frontage Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »